MAXION
LIVE

Serial Number

79412149

Owner

Maxion Therapeutics Limited

Attorney

Ben Natter

Filing Date

Oct 7, 2024

Add to watchlist:

No watchlists yet
View on USPTO

MAXION Trademark

Serial Number: 79412149

MAXION is a trademark filed by Maxion Therapeutics Limited on October 7, 2024. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently pending registration.

Owner Contact Info

Maxion Therapeutics Limited (4 trademarks)

C/O Mishcon de Reya,

Entity Type: 99

Trademark Details

Filing Date

October 7, 2024

Registration Date

Not Registered

Published for Opposition

February 17, 2026

Goods & Services

Scientific and technological services and research and design relating thereto, namely scientific research, analysis and testing in the fields of pharmaceuticals, biochemicals, polypeptides, antibodies, ion channel modulating antibodies, and G-protein-coupled receptor modulating antibodies and antibodies derived from mini-protein toxins; drug discovery and drug development services; conducting or providing research and development services for others in the field of antibodies; medical and scientific laboratory services relating to the production of antibodies, ion channel modulating and G-protein-coupled receptor modulating antibodies or antibodies derived from mini-protein toxins; antibody engineering; scientific research services relating to the discovery, preclinical and clinical development of therapeutic products; information, advisory and consultancy services in relation to all of the aforesaid

Medical services; medical diagnostic testing, analysis and diagnostic services for the treatment of patients in the field of antibodies; medical services for the treatment of diseases through the use of antibodies, ion channel modulating antibodies, and G-protein-coupled receptor modulating antibodies or antibodies derived from mini-protein toxins, or pharmaceuticals, drugs and pharmaceutical preparations derived from the aforesaid; information, advisory and consultancy services in relation to all of the aforesaid

Biochemicals, namely, polypeptides and engineered antibodies for scientific, laboratory or research purposes; polypeptides and engineered antibodies for use in the manufacture of pharmaceuticals and drugs; ion channel modulating and G-protein-coupled receptor modulating engineered antibodies for scientific, laboratory or research purposes; ion channel modulating and G-protein-coupled receptor modulating engineered antibodies for use in the manufacture of pharmaceuticals and drugs; engineered antibodies derived from mini-protein toxins for scientific, laboratory or research purposes; engineered antibodies derived from mini-protein toxins for use in the manufacture of pharmaceuticals and drugs

Pharmaceuticals and pharmaceutical preparations for the treatment of diseases and conditions associated with dysregulation of ion channel and G-protein-coupled receptor activity, in particular, preparations for the prevention and treatment of pain, autoimmunity, cardiovascular disease and cancer; drugs, namely, pharmaceutical preparations for the treatment of diseases and conditions associated with dysregulation of ion channel and G-protein-coupled receptor activity, in particular, those for use in the prevention and treatment of pain, autoimmunity, cardiovascular disease and cancer; antibodies for medical use; pharmaceuticals and drugs in the nature of pharmaceutical preparations incorporating antibodies, ion channel modulating antibodies, and G-protein-coupled receptor modulating antibodies or antibodies derived from mini-protein toxins for the treatment of diseases and conditions associated with dysregulation of ion channel and G-protein-coupled receptor activity, in particular, those for the prevention and treatment of pain, autoimmunity, cardiovascular disease and cancer; human vaccine preparations

Filing History

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 17, 2026 NPUB
PUBLISHED FOR OPPOSITION
Feb 17, 2026 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 11, 2026 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 27, 2026 CNSA
EXAMINER'S AMENDMENT ENTERED
Jan 27, 2026 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jan 27, 2026 GNEN
EXAMINERS AMENDMENT E-MAILED
Jan 27, 2026 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jan 27, 2026 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 22, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 21, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 21, 2025 TROA
REFUSAL PROCESSED BY IB
Jun 21, 2025 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jun 5, 2025 RFCS
REFUSAL PROCESSED BY MPU
Jun 5, 2025 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Apr 2, 2025 RFCR
NON-FINAL ACTION WRITTEN
Apr 1, 2025 CNRT
ASSIGNED TO EXAMINER
Mar 20, 2025 DOCK
APPLICATION FILING RECEIPT MAILED
Dec 13, 2024 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 13, 2024 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Dec 12, 2024 REPR